Y-mabs therapeutics.

Y-mAbs is a development-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates - naxitamab and omburtamab - which target …Y-mAbs Therapeutics ( NASDAQ: YMAB) is down some 65% since my coverage in May after it failed to win approval for neuroblastoma therapy I-omburtamab. The molecule Omblastys (omburtamab) was ...Y-mAbs Therapeutics GAAP EPS of -$0.64 beats by $0.08, revenue of $10.49M misses by $0.61M SA News Mon, May 09, 2022 Y-mAbs Therapeutics says CEO to quit, issues Danyelza revenue guidanceOct 17, 2023 · About Y-mAbs . Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for …

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a regulatory update for omburtamab, which is an investigational, monoclonal antibody ...NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third ...

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment …

Exhibit 99.1 Y-mAbs Announces Update on Omburtamab in DIPG New York, NY, November 19, 2020 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for …NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial ...18 tet 2023 ... Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company's second program within its SAYA ...Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein ...NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that its Board of Directors has …

Scientific Presentations. Dec 14, 2022. R&D Day: Company Presentation. Dec 16, 2020. R&D Day: Company Presentation. Dec 16, 2020. R&D Day: SADA Technology Platform. Dec 09, 2020. ESMO 2020: Efficacy and Updated Safety Results from Pivotal Phase 2 Trial 201 of Naxitamab.

When is Y-mAbs Therapeutics's earnings date? Y-mAbs Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off last year's report dates. Learn more on YMAB's earnings history.

Nov 13, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q. Quarterly Filings. 0001558370-23-018827.pdf. 0001558370-23-018827.rtf. 0001558370-23-018827.xls.Y-mAbs Therapeutics, Inc. Common Stock (YMAB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.NEW YORK , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage …Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform, and the SADA platform.Y-mAbs provides regulatory update on omburtamab for the treatment of patients with neuroblastoma. News release. Y-mAbs Therapeutic, Inc.; October 5, 2020. Accessed April 1, 2022. https://bit.ly ...Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors …

Leadership. Michael Rossi is President, Chief Executive Officer, and a member of the Board of Directors of Y-mAbs Therapeutics. Mr. Rossi has more than 30 years of radiopharmaceutical, drug development, commercialization, and people leadership experience on a global scale, most recently as President, Medical Group at Mirion Technologies. NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a Pre …2 korr 2019 ... combination with GM-CSF. Applicant Name: Y-mAbs Therapeutics, Inc. Meeting Chair: Ashley Ward, M.D.. FDA ATTENDEES.Nov 7, 2022 · NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ... Y-mAbs is committed to developing innovative immunotherapies to overcome cancer Y-mAbs isn’t like every other biopharmaceutical company. It was founded by Thomas Gad, President, Head of Business Development and Strategy, and, more importantly, the father of Daniella, a high-risk neuroblastoma survivor. ... Y-mAbs Therapeutics, Inc provides ...I-131 Omburtamab (Y-mAbs Therapeutics, Inc.) Omburtamab is a murine IgG1ҡ anti-B7H3 antibody 8H9 licensed by Y-mAbs Therapeutics from Memorial Sloan Kettering Cancer Center. Y-mAbs is developing this intraventricular CNS administered, I-131-labeled antibody as a treatment for relapsed or refractory neuroblastoma with CNS or leptomeningeal ...

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating …

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer …For the last reported quarter, it was expected that Y-mAbs Therapeutics, Inc. Would post a loss of $0.75 per share when it actually produced a loss of $0.63, delivering a surprise of +16%.The Y-mAbs Learning Program is a platform and online library designed to inform oncology nurses regarding the dosing, administration and safety information ...15 pri 2020 ... Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic ...WHAT IS DANYELZA? DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:Y-mAbs is striving to make a difference in the treatment of pediatric oncology. Connect with us. Contact Information In the US: Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York, NY 10169 USA Telephone: +1 646 885 8505 Email: [email protected] Y-mAbs Therapeutics, Inc. R&D Laboratories 111 Ideation Way Basement Floor, Room C-008 Nutley, NJ 07110 […] Nov 15, 2023 · Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call.

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation …

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is ...

NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter of ...Table of Contents. Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK, NY 10169 (646) 885-8505 . April 28, 2020 . Dear Stockholder: I am pleased to invite you to attend the 2020 Annual Meeting of Stockholders (the "Annual Meeting") of Y-mAbs Therapeutics, Inc., (the "Company"), which will be held on Thursday, June 11, 2020 at …NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131 I-omburtamab) for the ...Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call.Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products.Latest Y-mAbs Therapeutics Inc (YMAB:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and ...NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug …NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and ...Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.64 per share a year ago.

Y Mabs Therapeutics · Market Cap · P/E Ratio (ttm) · Forward P/E · Diluted EPS (ttm) · Dividends Per Share · Dividend Yield · Ex-Dividend Date.Nov 13, 2023. Quarterly report which provides a continuing view of a company's financial position. 10-Q. Quarterly Filings. 0001558370-23-018827.pdf. 0001558370-23-018827.rtf. 0001558370-23-018827.xls.About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products.Instagram:https://instagram. paypal applewarren buffett real estatewashington dental insurance plansannheiser busch stock Mar 30, 2023 · NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter ... companies like yieldstreetshort term health insurance kentucky Feb 22, 2021 · Naxitamab (DANYELZA®, naxitamab-gqgk) is a humanised (IgG1) anti-GD2 (hu3F8) monoclonal antibody was developed by the Memorial Sloan Kettering Cancer Center (with commercial rights licenced to Y-mAbs therapeutics Inc.) for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was recently granted accelerated approval by the US FDA for marketing as treatment ... immediate health insurance texas NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ...If you purchased or acquired Y-mAbs common stock, and/or would like to discuss your legal rights and options please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact ...